Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Shimomura, A., Yamamoto, N., Kondo, S., Fujiwara, Y., Suzuki, S., Yanagitani, N., Horiike, A., Kitazono, S., Ohyanagi, F., Doi, T., et al. (2019). First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. Mol cancer ther, Vol.18 (3), pp. 531-540.  show abstract

Moss, C.A., Cojocaru, E., Hanwell, J., Ward, S., Xu, W., van Zyl, M., O'Leary, L., de Bono, J.S., Banerji, U., Kaye, S.B., et al. (2019). Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services. Eur j cancer, Vol.114, pp. 97-106.  show abstract

Ameratunga, M., Chénard-Poirier, M., Moreno Candilejo, I., Pedregal, M., Lui, A., Dolling, D., Aversa, C., Ingles Garces, A., Ang, J.E., Banerji, U., et al. (2018). Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. Eur j cancer, Vol.89, pp. 56-63.  show abstract

Banerji, U., Dean, E.J., Pérez-Fidalgo, J.A., Batist, G., Bedard, P.L., You, B., Westin, S.N., Kabos, P., Garrett, M.D., Tall, M., et al. (2018). A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers. Clin cancer res, Vol.24 (9), pp. 2050-2059.  show abstract

Sundar, R., Custodio, A., Petruckevich, A., Chénard-Poirier, M., Ameratunga, M., Collins, D., Lim, J., Kaye, S.B., Tunariu, N., Banerji, U., et al. (2018). Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. Clin oncol (r coll radiol), Vol.30 (3), pp. 185-191.  show abstract

Dean, E., Banerji, U., Schellens, J.H., Krebs, M.G., Jimenez, B., van Brummelen, E., Bailey, C., Casson, E., Cripps, D., Cullberg, M., et al. (2018). A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. Cancer chemother pharmacol, Vol.81 (5), pp. 873-883.  show abstract

McVeigh, T.P., Sundar, R., Diamantis, N., Kaye, S.B., Banerji, U., Lopez, J.S., de Bono, J., van der Graaf, W.T. & George, A.J. (2018). The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials. Eur j cancer, Vol.95, pp. 20-29.  show abstract

Dillon, M.T., Boylan, Z., Smith, D., Guevara, J., Mohammed, K., Peckitt, C., Saunders, M., Banerji, U., Clack, G., Smith, S.A., et al. (2018). PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. Clin transl radiat oncol, Vol.12, pp. 16-20.  show abstract

Coleman, N., Michalarea, V., Alken, S., Rihawi, K., Lopez, R.P., Tunariu, N., Petruckevitch, A., Molife, L.R., Banerji, U., De Bono, J.S., et al. (2018). Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience. J neurooncol, Vol.139 (1), pp. 107-116.  show abstract

Sundar, R., McVeigh, T., Dolling, D., Petruckevitch, A., Diamantis, N., Ang, J.E., Chenard-Poiriér, M., Collins, D., Lim, J., Ameratunga, M., et al. (2018). Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. Eur j cancer, Vol.101, pp. 55-61.  show abstract

Ingles Garces, A.H., Ang, J.E., Ameratunga, M., Chénard-Poirier, M., Dolling, D., Diamantis, N., Seeramreddi, S., Sundar, R., de Bono, J., Lopez, J., et al. (2018). A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. Eur j cancer, Vol.104, pp. 32-38.  show abstract

Basu, B., Krebs, M.G., Sundar, R., Wilson, R.H., Spicer, J., Jones, R., Brada, M., Talbot, D.C., Steele, N., Ingles Garces, A.H., et al. (2018). Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer. Ann oncol, .  show abstract

Lopez, J.S. & Banerji, U. (2017). Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat rev clin oncol, Vol.14 (1), pp. 57-66.  show abstract

Papadatos-Pastos, D., Roda, D., De Miguel Luken, M.J., Petruckevitch, A., Jalil, A., Capelan, M., Michalarea, V., Lima, J., Diamantis, N., Bhosle, J., et al. (2017). Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. Eur j cancer, Vol.75, pp. 56-62.  show abstract

Brown, J.S. & Banerji, U. (2017). Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol ther, Vol.172, pp. 101-115.  show abstract

George, A., Kristeleit, R., Rafii, S., Michie, C.O., Bowen, R., Michalarea, V., van Hagen, T., Wong, M., Rallis, G., Molife, L.R., et al. (2017). Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. Eur j cancer, Vol.76, pp. 52-59.  show abstract

Vormoor, B., Veal, G.J., Griffin, M.J., Boddy, A.V., Irving, J., Minto, L., Case, M., Banerji, U., Swales, K.E., Tall, J.R., et al. (2017). A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatr blood cancer, Vol.64 (6).  show abstract

Zangarini, M., Berry, P., Sludden, J., Raynaud, F.I., Banerji, U., Jones, P., Edwards, D. & Veal, G.J. (2017). Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma. Bioanalysis, Vol.9 (13), pp. 1001-1010.  show abstract

Tucker, E.R., Tall, J.R., Danielson, L.S., Gowan, S., Jamin, Y., Robinson, S.P., Banerji, U. & Chesler, L. (2017). Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. Mol oncol, Vol.11 (8), pp. 996-1006.  show abstract

Capelan, M., Roda, D., Geuna, E., Rihawi, K., Bodla, S., Kaye, S.B., Bhosle, J., Banerji, U., O'Brien, M., de Bono, J.S., et al. (2017). Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. Lung cancer, Vol.111, pp. 6-11.  show abstract

Ang, J.E., Pal, A., Asad, Y.J., Henley, A.T., Valenti, M., Box, G., de Haven Brandon, A., Revell, V.L., Skene, D.J., Venturi, M., et al. (2017). Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. Mol cancer ther, Vol.16 (10), pp. 2315-2323.  show abstract

Hyman, D.M., Smyth, L.M., Donoghue, M.T., Westin, S.N., Bedard, P.L., Dean, E.J., Bando, H., El-Khoueiry, A.B., Pérez-Fidalgo, J.A., Mita, A., et al. (2017). AKT Inhibition in Solid Tumors With AKT1 Mutations. J clin oncol, Vol.35 (20), pp. 2251-2259.  show abstract

Wagner, A.J., Banerji, U., Mahipal, A., Somaiah, N., Hirsch, H., Fancourt, C., Johnson-Levonas, A.O., Lam, R., Meister, A.K., Russo, G., et al. (2017). Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. J clin oncol, Vol.35 (12), pp. 1304-1311.  show abstract

Wong Te Fong, A.-., Thavasu, P., Gagrica, S., Swales, K.E., Leach, M.O., Cosulich, S.C., Chung, Y.-. & Banerji, U. (2017). Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models. Oncotarget, Vol.8 (69), pp. 113874-113884.  show abstract

Perez-Lopez, R., Roda, D., Jimenez, B., Brown, J., Mateo, J., Carreira, S., Lopez, J., Banerji, U., Molife, L.R., Koh, D.-., et al. (2017). High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget, Vol.8 (61), pp. 104430-104443.  show abstract

Minchom, A., Thavasu, P., Ahmad, Z., Stewart, A., Georgiou, A., O'Brien, M.E., Popat, S., Bhosle, J., Yap, T.A., de Bono, J., et al. (2017). A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. Plos one, Vol.12 (10), p. e0186106.  show abstract

Roda, D., Jimenez, B. & Banerji, U. (2016). Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?. Clin cancer res, Vol.22 (9), pp. 2127-2132.  show abstract

Khan, K.H., Yap, T.A., Ring, A., Molife, L.R., Bodla, S., Thomas, K., Zivi, A., Smith, A., Judson, I., Banerji, U., et al. (2016). Phase I trial outcomes in older patients with advanced solid tumours. Br j cancer, Vol.114 (3), pp. 262-268.  show abstract

Khan, K.H., Wong, M., Rihawi, K., Bodla, S., Morganstein, D., Banerji, U. & Molife, L.R. (2016). Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management. Oncologist, Vol.21 (7), pp. 855-860.  show abstract

Banerji, U. & Workman, P. (2016). Critical parameters in targeted drug development: the pharmacological audit trail. Semin oncol, Vol.43 (4), pp. 436-445.  show abstract

Jamieson, D., Griffin, M.J., Sludden, J., Drew, Y., Cresti, N., Swales, K., Merriman, M., Allen, R., Bevan, P., Buerkle, M., et al. (2016). A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. Eur j cancer, Vol.68, pp. 1-10.  show abstract

Dolly, S.O., Kalaitzaki, E., Puglisi, M., Stimpson, S., Hanwell, J., Fandos, S.S., Stapleton, S., Ansari, T., Peckitt, C., Kaye, S., et al. (2016). A study of motivations and expectations of patients seen in phase 1 oncology clinics. Cancer, Vol.122 (22), pp. 3501-3508.  show abstract

Diamantis, N. & Banerji, U. (2016). Antibody-drug conjugates--an emerging class of cancer treatment. Br j cancer, Vol.114 (4), pp. 362-367.  show abstract

Broutin, S., Stewart, A., Thavasu, P., Paci, A., Bidart, J.-. & Banerji, U. (2016). Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer. Br j cancer, Vol.115 (5), pp. 549-552.  show abstract

Puglisi, M., Stewart, A., Thavasu, P., Frow, M., Carreira, S., Minchom, A., Punwani, R., Bhosle, J., Popat, S., Ratoff, J., et al. (2016). Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. Oncology, Vol.90 (5), pp. 280-288.  show abstract

Geuna, E., Roda, D., Rafii, S., Jimenez, B., Capelan, M., Rihawi, K., Montemurro, F., Yap, T.A., Kaye, S.B., De Bono, J.S., et al. (2015). Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. Br j cancer, Vol.113 (11), pp. 1541-1547.  show abstract

Basu, B., Dean, E., Puglisi, M., Greystoke, A., Ong, M., Burke, W., Cavallin, M., Bigley, G., Womack, C., Harrington, E.A., et al. (2015). First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clin cancer res, Vol.21 (15), pp. 3412-3419.  show abstract

Stewart, A., Thavasu, P., de Bono, J.S. & Banerji, U. (2015). Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors. Ann oncol, Vol.26 (7), pp. 1504-1510.  show abstract

Frenel, J.S., Carreira, S., Goodall, J., Roda, D., Perez-Lopez, R., Tunariu, N., Riisnaes, R., Miranda, S., Figueiredo, I., Nava-Rodrigues, D., et al. (2015). Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin cancer res, Vol.21 (20), pp. 4586-4596.  show abstract

Tolcher, A.W., Khan, K., Ong, M., Banerji, U., Papadimitrakopoulou, V., Gandara, D.R., Patnaik, A., Baird, R.D., Olmos, D., Garrett, C.R., et al. (2015). Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin cancer res, Vol.21 (4), pp. 739-748.  show abstract

Rafii, S., Roda, D., Geuna, E., Jimenez, B., Rihawi, K., Capelan, M., Yap, T.A., Molife, L.R., Kaye, S.B., de Bono, J.S., et al. (2015). Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. Clin cancer res, Vol.21 (8), pp. 1869-1876.  show abstract

Wagner, A.J., Banerji, U., Mahipal, A., Somaiah, N., Hirsch, H.A., Fancourt, C., Levonas, A., Lam, R., Meister, A., Kemp, R.K., et al. (2015). A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors. Journal of clinical oncology, Vol.33 (15).

Strimpakos, A.S., Banerji, U., Thavasu, P., Tsilimagou, A., Psyrri, A. & Syrigos, K.N. (2015). Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC. Oncology, Vol.89 (1), pp. 53-59.  show abstract

Blagden, S., Omlin, A., Josephs, D., Stavraka, C., Zivi, A., Pinato, D.J., Anthoney, A., Decordova, S., Swales, K., Riisnaes, R., et al. (2014). First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. Clin cancer res, Vol.20 (23), pp. 5908-5917.  show abstract

Gaykema, S.B., Schröder, C.P., Vitfell-Rasmussen, J., Chua, S., Oude Munnink, T.H., Brouwers, A.H., Bongaerts, A.H., Akimov, M., Fernandez-Ibarra, C., Lub-de Hooge, M.N., et al. (2014). 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin cancer res, Vol.20 (15), pp. 3945-3954.  show abstract

Puglisi, M., Thavasu, P., Stewart, A., de Bono, J.S., O'Brien, M.E., Popat, S., Bhosle, J. & Banerji, U. (2014). AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines. Lung cancer, Vol.85 (2), pp. 141-146.  show abstract

Khan, K., Ang, J.E., Starling, N., Sclafani, F., Shah, K., Judson, I., Molife, L.R., Banerji, U., de Bono, J.S., Cunningham, D., et al. (2014). Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. Gastric cancer, Vol.17 (4), pp. 621-629.  show abstract

Saif, M.W., Takimoto, C., Mita, M., Banerji, U., Lamanna, N., Castro, J., O'Brien, S., Stogard, C. & Von Hoff, D. (2014). A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. Clin cancer res, Vol.20 (2), pp. 445-455.  show abstract

Venugopal, B., Baird, R., Kristeleit, R.S., Plummer, R., Cowan, R., Stewart, A., Fourneau, N., Hellemans, P., Elsayed, Y., Mcclue, S., et al. (2013). A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors. Clinical cancer research, Vol.19 (15), pp. 4262-4272.

Sessa, C., Shapiro, G.I., Bhalla, K.N., Britten, C., Jacks, K.S., Mita, M., Papadimitrakopoulou, V., Pluard, T., Samuel, T.A., Akimov, M., et al. (2013). First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors. Clinical cancer research, Vol.13 (19), pp. 3671-3680.

Hong, D.S., Banerji, U., Tavana, B., George, G.C., Aaron, J. & Kurzrock, R. (2013). Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer treat rev, Vol.39 (4), pp. 375-387.  show abstract

Martinez-Garcia, M., Banerji, U., Albanell, J., Bahleda, R., Dolly, S., Kraeber-Bodéré, F., Rojo, F., Routier, E., Guarin, E., Xu, Z.-., et al. (2012). First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin cancer res, Vol.18 (17), pp. 4806-4819.  show abstract

Banerji, U., van Doorn, L., Papadatos-Pastos, D., Kristeleit, R., Debnam, P., Tall, M., Stewart, A., Raynaud, F., Garrett, M.D., Toal, M., et al. (2012). A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin cancer res, Vol.18 (9), pp. 2687-2694.  show abstract

Pacey, S., Gore, M., Chao, D., Banerji, U., Larkin, J., Sarker, S., Owen, K., Asad, Y., Raynaud, F., Walton, M., et al. (2012). A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest new drugs, Vol.30 (1), pp. 341-349.  show abstract

Carden, C.P., Stewart, A., Thavasu, P., Kipps, E., Pope, L., Crespo, M., Miranda, S., Attard, G., Garrett, M.D., Clarke, P.A., et al. (2012). The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol cancer ther, Vol.11 (7), pp. 1609-1617.  show abstract

Molife, L.R., Alam, S., Olmos, D., Puglisi, M., Shah, K., Fehrmann, R., Trani, L., Tjokrowidjaja, A., de Bono, J.S., Banerji, U., et al. (2012). Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. Ann oncol, Vol.23 (8), pp. 1968-1973.  show abstract

Al-Lazikani, B., Banerji, U. & Workman, P. (2012). Combinatorial drug therapy for cancer in the post-genomic era. Nat biotechnol, Vol.30 (7), pp. 679-692.  show abstract

Ang, J.E., Kaye, S. & Banerji, U. (2012). Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials. Curr drug targets, Vol.13 (12), pp. 1525-1534.  show abstract

Moreno Garcia, V., Thavasu, P., Blanco Codesido, M., Molife, L.R., Vitfell Pedersen, J., Puglisi, M., Basu, B., Shah, K., Iqbal, J., de Bono, J.S., et al. (2012). Association of creatine kinase and skin toxicity in phase I trials of anticancer agents. Br j cancer, Vol.107 (11), pp. 1797-1800.  show abstract

Rodrigues, L.M., Chung, Y.-., Al Saffar, N.M., Sharp, S.Y., Jackson, L.E., Banerji, U., Stubbs, M., Leach, M.O., Griffiths, J.R. & Workman, P., et al. (2012). Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy. Bmc res notes, Vol.5, p. 250.  show abstract

Naing, A., Aghajanian, C., Raymond, E., Olmos, D., Schwartz, G., Oelmann, E., Grinsted, L., Burke, W., Taylor, R., Kaye, S., et al. (2012). Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br j cancer, Vol.107 (7), pp. 1093-1099.  show abstract

Rodrigues, L.M., Chung, Y.-., Al Saffar, N.M., Sharp, S.Y., Jackson, L.E., Banerji, U., Stubbs, M., Leach, M.O., Griffiths, J.R. & Workman, P., et al. (2012). Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy. Bmc research notes, Vol.5 (1), pp. 250-250.

Perkins, G., Yap, T.A., Pope, L., Cassidy, A.M., Dukes, J.P., Riisnaes, R., Massard, C., Cassier, P.A., Miranda, S., Clark, J., et al. (2012). Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. Plos one, Vol.7 (11), p. e47020.  show abstract

Basu, B., Vitfell-Pedersen, J., Moreno Garcia, V., Puglisi, M., Tjokrowidjaja, A., Shah, K., Malvankar, S., Anghan, B., de Bono, J.S., Kaye, S.B., et al. (2012). Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials. Oncology, Vol.83 (4), pp. 177-182.  show abstract

Papadatos-Pastos, D. & Banerji, U. (2011). Revisiting the role of molecular targeted therapies in patients with brain metastases. J neurooncol, Vol.105 (3), pp. 467-474.  show abstract

Pacey, S., Wilson, R.H., Walton, M., Eatock, M.M., Hardcastle, A., Zetterlund, A., Arkenau, H.-., Moreno-Farre, J., Banerji, U., Roels, B., et al. (2011). A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin cancer res, Vol.17 (6), pp. 1561-1570.  show abstract

Blanco-Codesido, M., Brunetto, A., Frentzas, S., Garcia, V.M., Papadatos-Pastos, D., Pedersen, J.V., Trani, L., Puglisi, M., Sarker, D., Molife, L.R., et al. (2011). Clinical outcome of patients with metastasic melanoma undergoing phase I clinical trials. Journal of clinical oncology, Vol.29 (15).

Blanco Codesido, M., Tesainer Brunetto, A., Frentzas, S., Moreno Garcia, V., Papadatos-Pastos, D., Pedersen, J.V., Trani, L., Puglisi, M., Molife, L.R. & Banerji, U., et al. (2011). Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials. Oncology, Vol.81 (2), pp. 135-140.  show abstract

Banerji, U., Camidge, D.R., Verheul, H.M., Agarwal, R., Sarker, D., Kaye, S.B., Desar, I.M., Timmer-Bonte, J.N., Eckhardt, S.G., Lewis, K.D., et al. (2010). The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin cancer res, Vol.16 (5), pp. 1613-1623.  show abstract

Carden, C.P., Sarker, D., Postel-Vinay, S., Yap, T.A., Attard, G., Banerji, U., Garrett, M.D., Thomas, G.V., Workman, P., Kaye, S.B., et al. (2010). Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. Drug discov today, Vol.15 (3-4), pp. 88-97.  show abstract

Brunetto, A.T., Ang, J.E., Olmos, D., Tan, D., Barriuso, J., Arkenau, H.-., Yap, T.A., Molife, L.R., Banerji, U., de Bono, J., et al. (2010). A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition. Eur j cancer, Vol.46 (15), pp. 2739-2745.  show abstract

Larkin, J.M., Ferguson, T.R., Pickering, L.M., Edmonds, K., James, M.G., Thomas, K., Banerji, U., Berns, B., de Boer, C. & Gore, M.E., et al. (2010). A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br j cancer, Vol.103 (8), pp. 1149-1153.  show abstract

Banerji, U. (2009). Heat shock protein 90 as a drug target: some like it hot. Clin cancer res, Vol.15 (1), pp. 9-14.  show abstract

Carden, C.P., Banerji, U., Kaye, S.B., Workman, P. & de Bono, J.S. (2009). From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin pharmacol ther, Vol.85 (2), pp. 131-133.  show abstract

Postel-Vinay, S., Arkenau, H.-., Olmos, D., Ang, J., Barriuso, J., Ashley, S., Banerji, U., De-Bono, J., Judson, I. & Kaye, S., et al. (2009). Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?. Br j cancer, Vol.100 (9), pp. 1373-1378.  show abstract

Tan, D.S., Thomas, G.V., Garrett, M.D., Banerji, U., de Bono, J.S., Kaye, S.B. & Workman, P. (2009). Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer j, Vol.15 (5), pp. 406-420.  show abstract

Banerji, U., Affolter, A., Judson, I., Marais, R. & Workman, P. (2008). BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol cancer ther, Vol.7 (4), pp. 737-739.  show abstract

Banerji, U., Sain, N., Sharp, S.Y., Valenti, M., Asad, Y., Ruddle, R., Raynaud, F., Walton, M., Eccles, S.A., Judson, I., et al. (2008). An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer chemother pharmacol, Vol.62 (5), pp. 769-778.  show abstract

Banerji, U., de Bono, J., Judson, I., Kaye, S. & Workman, P. (2008). Biomarkers in early clinical trials: the committed and the skeptics. Clin cancer res, Vol.14 (8), p. 2512.

Maloney, A., Clarke, P.A., Naaby-Hansen, S., Stein, R., Koopman, J.-., Akpan, A., Yang, A., Zvelebil, M., Cramer, R., Stimson, L., et al. (2007). Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer res, Vol.67 (7), pp. 3239-3253.  show abstract

Banerji, U., Kuciejewska, A., Ashley, S., Walsh, G., O'Brien, M., Johnston, S. & Smith, I. (2007). Factors determining outcome after third line chemotherapy for metastatic breast cancer. Breast, Vol.16 (4), pp. 359-366.  show abstract

Yap, Y.S., Kendall, A., Walsh, G., Banerji, U., Johnston, S.R., Smith, I.E. & O'Brien, M. (2007). Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?. Breast, Vol.16 (4), pp. 420-424.  show abstract

Spicer, J., Banerji, U., Hanwell, J. & Judson, I. (2006). Stable disease for four years in metastatic malignant melanoma treated with the heat shock protein inhibitor 17-AAG. Target oncol, Vol.1 (1), pp. 54-55.  show abstract

Banerji, U., Ashley, S., Coward, J., Hughes, S., Zee, Y., Benepal, T., Norton, A., Eisen, T. & O'Brien, M. (2006). The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer. Lung cancer, Vol.54 (3), pp. 371-377.  show abstract

Banerji, U., Walton, M., Raynaud, F., Grimshaw, R., Kelland, L., Valenti, M., Judson, I. & Workman, P. (2005). Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin cancer res, Vol.11 (19 Pt 1), pp. 7023-7032.  show abstract

Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., et al. (2005). Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J clin oncol, Vol.23 (18), pp. 4152-4161.  show abstract

Chung, Y.-., Troy, H., Banerji, U., Jackson, L.E., Walton, M.I., Stubbs, M., Griffiths, J.R., Judson, I.R., Leach, M.O., Workman, P., et al. (2003). Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J natl cancer inst, Vol.95 (21), pp. 1624-1633.  show abstract

Banerji, U., Judson, I. & Workman, P. (2003). The clinical applications of heat shock protein inhibitors in cancer - present and future. Curr cancer drug targets, Vol.3 (5), pp. 385-390.  show abstract

Clarke, P.A., Hostein, I., Banerji, U., Stefano, F.D., Maloney, A., Walton, M., Judson, I. & Workman, P. (2000). Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene, Vol.19 (36), pp. 4125-4133.  show abstract

Geh, J.I., Glynne-Jones, R., Kwok, Q.S., Banerji, U., Livingstone, J.I., Townsend, E.R., Harrison, R.A. & Mitchell, I.C. (2000). Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma. Clin oncol (r coll radiol), Vol.12 (3), pp. 182-187.  show abstract

Ganapati, R., Pai, V.V., Banerji, U., Thomas, J. & Saha, B. (1997). A multicenter study of recombinant interferon-alpha 2b in the treatment of multibacillary leprosy. Int j lepr other mycobact dis, Vol.65 (4), pp. 495-497.


Books

Banerji, U., Judson, I. & Workman, P. (2004). Molecular targets, New Jersey, Humana Press, ISBN: 978-1588291776.


Book Chapters

Stewart, A. & Banerji, U. (2017). Utilizing the Luminex Magnetic Bead-Based Suspension Array for Rapid Multiplexed Phosphoprotein Quantification. . (pp. 119-131).

Ong, M. & Banerji, U. (2016). Principles of clinical pharmacology: introduction to pharmacokinetics and pharmacodynamics. In Kerr, D.J., Haller, D.G., van de Velde, C.J. & Baumann, M. (Eds.), Oxford Textbook of Oncology. 3rd (pp. 209-219). Oxford University Press, ISBN: 9780191065101.

Kumar, R., Twelves, C. & Banerji, U. (2015). Phase I trials in special populations and circumstances. In Eisenhaur, E., Twelves, C. & Buyse, M. (Eds.), Phase I Cancer Clinical Trials A Practical Guide. 2nd (pp. 104-368). New York, USA, Oxford University Press, ISBN: 9780199359035.

Pacey, S., Banerji, U., Judson, I. & Workman, P. (2006). Hsp90 inhibitors in the clinic. . (pp. 331-358).